Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EPS (Basic) (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EPS (Basic) for 2 consecutive years, with $0.41 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 133.33% to $0.41 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.24 through Dec 2025, down 75.14% year-over-year, with the annual reading at -$0.23 for FY2025, 98.76% up from the prior year.
  • EPS (Basic) for Q4 2025 was $0.41 at Neuphoria Therapeutics, up from -$4.41 in the prior quarter.
  • The five-year high for EPS (Basic) was $6.55 in Q1 2025, with the low at -$5.79 in Q2 2025.